Portfolio.
Over the years, Waterman Ventures has invested in, and exited, a diverse set of companies across industries, across different stages of their lifecycle, with both local as well as global presence.
Current investments
Qualinx
Qualinx has developed world's lowest power GNSS Solutions, enabled by breakthrough Digital RF and Software Defined Radio technology
Yellow Door Energy
Yellow Door Energy is the leading distributed Commercial & Industrial solar platform in the Middle East and Africa region with around 200MW of secured production capacity
U-Needle
Uneedle has developed a microneedle injection technology that unlocks the potential of precise, superficial drug delivery - such as intradermal and suprachoroidal - enabling improved therapies
Ceradis
Ceradis develops (biological) compounds and formulation additives that boost or replace existing chemical active ingredients, resulting in a reduced rate of chemicals use per hectare and lower residues
Neurophyxia
Neurophyxia is a clinical drug development company that aims to reduce the deleterious effects of oxygen shortage in the brain due to stroke (in adults), cardiac arrest (in adults) and birth asphyxia in newborns
Modra
Modra Pharmaceuticals aims to transform taxane therapy by developing (chemo)therapies that are effective, less toxic and can be taken at home
Lead Pharma
Lead Pharma is a clinical-stage pharmaceutical research & development company that designs and develops innovative small-molecule therapies to treat autoimmune diseases and cancer
FutureChemistry
FutureChemistry is a radiochemistry technology and consultancy provider assisting radionuclide and radiopharmaceutical development and production in nuclear medicine
Fluitec
Fluitec develops and sells solutions that maximize the life and performance of lubricants and machinery resulting in a positive environmental and economic impact
ProductIP
ProductIP is a global company that offers the most comprehensive product compliance platform
Acces2bone
Access2Bone develops highly effective DBM based bone void fillers for bone regeneration treatment
Alveron Pharma
Alveron Pharma develops a universal anticoagulant reversal drug which is a potential break-through in the treatment of haemorrhagic stroke
Looking to grow your company?
We are always on the lookout for promising new companies led by strong teams. If you are an ambitious entrepreneur looking to grow your company, please don’t hesitate to contact us. We consider venture, growth as well as buyout investments.
